NCT02750202 2026-01-23
TheraVACCS
University of Pretoria
Phase 3 Completed
Clinical Trials
39 trialsNCT04537156 2025-11-21
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 3 Active not recruiting
NCT04635423 2025-08-11
V503-064
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00092534 2025-08-01
FUTURE II
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT05056402 2025-07-22
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Xiamen University
Phase 3 Active not recruiting
NCT06465914 2024-12-12
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Active not recruiting
NCT04422366 2024-06-07
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT04895020 2024-04-17
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05027776 2024-04-17
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05372016 2023-11-24
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT05584332 2023-07-21
A Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Terminated
NCT04782895 2023-06-15
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Xiamen University
Phase 3 Completed
NCT05314023 2023-01-19
V503-053
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT05580341 2022-10-28
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Shanghai Zerun Biotechnology Co.,Ltd
Phase 3 Unknown
NCT04425291 2022-02-25
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT05156541 2021-12-14
ING-HPV-1
SPP Pharmaclon Ltd.
Phase 3 Completed
NCT03289260 2020-09-23
AdAM
Medical University Innsbruck
Phase 3 Unknown
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03158220 2019-11-21
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03853785 2019-03-12
Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
Assiut University
Phase 3 Unknown
NCT00543543 2018-11-27
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01047345 2018-11-27
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ (V503-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01651949 2018-11-27
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01245764 2018-11-14
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00090285 2018-08-23
V501-020
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03296397 2018-02-27
CONDYVAC
Assistance Publique - Hôpitaux de Paris
Phase 3 Unknown
NCT03153566 2017-05-17
Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients
Assiut University
Phase 3 Unknown
NCT00092482 2017-03-22
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00517309 2017-03-22
FUTURE
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00092521 2015-09-25
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00501137 2015-04-10
BCGov-01
University of British Columbia
Phase 3 Completed
NCT00092495 2015-01-13
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01111344 2012-05-08
Glizigen-Viudid-External Anogenital Warts in Children and Adolescents
Catalysis SL
Phase 3 Completed
NCT00735462 2011-07-20
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00674739 2011-05-24
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00999986 2009-11-25
Low Dose Cyclophosphamide Treats Genital Warts
Huazhong University of Science and Technology
Phase 3 Completed
NCT00449982 2007-03-21
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
MediGene
Phase 3 Completed